Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Matap Ii, LLC

Approvalsnovel device granted (FDA De Novo)21 Aug 2026

Matap Ii, LLC

21 Aug 2026: Novel device granted (FDA De Novo) · Avulux. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
21 Aug 2026
Device
Avulux
Specialty
Neurology
Product Code
QEO
Country
United States
Location
Aventura, FL
Submitted
2025-06-23
Reference
DEN250026
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Matap Ii, LLC

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Matap Ii, LLC in our registers.

More in Neurology

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.